comparemela.com

Sling Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sling Therapeutics Announces Publication Demonstrating Attenuation of Pathologic Bone Marrow Activity with Linsitinib in a Mouse Model of Thyroid Eye Disease

/PRNewswire/ Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid.

Adam daleyJeffrey kentTanja ecksteinDepartment of orthopticsPrnewswire sling therapeutics incTherapeutics incBerry company public relationsOrbital centerGilmartin groupUniversity eye hospital essenThyroid eye diseaseReconstructive surgeryChief medical officerSling therapeutics

Sling Therapeutics Appoints Raymond Douglas, M D , Ph D , as Chief Scientific Officer

/PRNewswire/ Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of linsitinib, an oral small molecule for the treatment.

Jules stein eye instituteUnited statesBeverly hillsLos angelesRaymond douglasAdam daleyRyan zeidanGilmartin groupBerry company public relationsUniversity of pennsylvania school medicineDrug administrationUniversity of michiganTherapeutics incScheie eye institute penn presbyterianUniversity of pennsylvaniaSling therapeutics

Sling Therapeutics to Participate in the Stifel Virtual I&I Summit

/PRNewswire/ Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid.

Ryan zeidanAdam daleyGilmartin groupTherapeutics incPrnewswire sling therapeutics incBerry company public relationsChief executive officerSling therapeutics

Sling Therapeutics Presents Preclinical Data Demonstrating Treatment with Linsitinib Limits Progression of Thyroid Eye Disease at 45th Annual Meeting of European Thyroid Association

/PRNewswire/ Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid.

United kingdomUnited statesRyan zeidanAdam daleyTherapeutics incMeeting of the european thyroid associationBerry company public relationsPrnewswire sling therapeutics incGilmartin groupAnnual meetingEuropean thyroid associationChief executive officerThyroid eye diseaseSling therapeutics

Sling Therapeutics Initiates Enrollment in Phase 2b LIDS Clinical Trial Evaluating Linsitinib in Thyroid Eye Disease

- First oral IGF-1R inhibitor to enter late-stage clinical trials for thyroid eye disease –- Global study being conducted in the U.S., Canada, UK,.

United statesUnited kingdomBeverly hillsRobin schmidtRyan zeidanAdam daleyGeorgej kahalyRaymond douglasTherapeutics incBerry company public relationsJohannes gutenberg university medical centerSling therapeuticsChief executive officerGrave ophthalmopathy quality

vimarsana © 2020. All Rights Reserved.